Yamanouchi Subscribes to Celera s Discovery System | GenomeWeb

NEW YORK, June 25 - Yamanouchi Pharmaceutical, the third largest drug maker in Japan, has signed a five-year subscription to Celera's Discovery System, the company's genomics database and bioinformatics tools.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.